摘要
目的 探讨骨髓增殖性肿瘤患者JAK2及MPL及CALR基因突变的位点,及患者的临床特点。方法 选取我院2014年2月-2015年5月收治的骨髓增殖性肿瘤患者100例,通过测序法测定患者CALR基因突变,通过AS-PCR法检测患者骨髓中JAK2及MPL基因突变。结果 所有患者MPL基因突变阴性;PV患者JAK2基因突变发生率91.9%,CALR基因突变阴性;ET患者JAK2基因突变发生率41.2%,CALR基因突变发生率为32.4%;PMF患者JAK2基因突变发生率为44.8%,CALR基因突变发生率为31.0%。结论 骨髓增殖性肿瘤患者发生CALR基因突变的患者与发生JAK2、MPL基因突变的患者比较,更有可能获得较好的预后效果。
Objective To study the patients with tumor in bone marrow hyperplastic JAK2 and MPL and CALR gene mutation sites, and the clinical characteristics of patients.Methods 100 cases of bone marrow cancer patients treated in our hospital from February 2014 to May 2015 were selected. The mutation of CALR gene was determined by sequencing method. Detection of JAK2 and MPL gene mutations in bone marrow of patients by AS-PCR.Results All patients MPL gene mutation negative. PV JAK2 gene mutation rate was 91.9%, CALR gene mutation negative. ET JAK2 gene mutation rate was 41.2%, CALR gene mutation rate was 32.4%. Patients with PMF JAK2 gene mutation rate was 44.8%, CALR gene mutation rate was 31.0%.Conclusion Bone marrow in patients with hyperplastic tumor CALR gene mutations in patients with JAK2, MPL gene mutation of patients were compared, and are more likely to achieve good prognosis.
出处
《中国继续医学教育》
2016年第32期104-105,共2页
China Continuing Medical Education
关键词
骨髓增殖性肿瘤
基因突变
位点
临床分析
Marrow hyperplastic tumor
Gene mutation
Site
Clinical analysis
